Key Highlights
- Morgan Stanley maintains Overweight stance on Eli Lilly (LLY) with price target of $1,313
- Weekly Mounjaro prescriptions reached approximately 724,500, climbing from roughly 705,300
- Zepbound prescriptions surged to around 598,100, up from approximately 500,900
- Lilly captures roughly 60% of weekly new prescription market share in GLP-1 category
- Fourth quarter EPS reached $7.54, surpassing expectations, while revenue climbed 42.6% annually
Eli Lilly’s dominant weight-loss and diabetes treatments, Mounjaro and Zepbound, demonstrated continued prescription momentum during the week concluded February 27, 2026, based on IQVIA data referenced by Morgan Stanley analysts.
Mounjaro prescription volume touched approximately 724,500 for the reporting period, representing growth from the previous week’s 705,300. New Mounjaro prescriptions totaled roughly 361,600, compared with 352,700 in the preceding week.
Zepbound demonstrated even more substantial weekly gains. Overall prescriptions climbed to about 598,100, advancing from 500,900 the week prior. New prescriptions expanded to 328,300 from 298,600.
Morgan Stanley maintained its Overweight assessment on LLY while reaffirming the $1,313 price objective. The investment bank projects approximately 7% potential upside to its 2026 forecasts for both medications.
Total GLP-1 prescription volume for Lilly and Novo Nordisk expanded roughly 30% on a year-over-year basis, demonstrating robust ongoing demand throughout the therapeutic class.
Lilly’s complete GLP-1 product portfolio — encompassing Mounjaro, Zepbound, and Trulicity — captured approximately 60% of new weekly prescription market share, edging higher from 59% in the previous reporting period.
Financial Performance Overview
LLY delivered Q4 EPS of $7.54, exceeding the $7.48 analyst consensus by $0.06. Quarterly revenue reached $19.29 billion, significantly surpassing the $17.85 billion estimate. This represented a 42.6% increase compared to the year-ago period.
Management established FY2026 guidance at $33.50–$35.00 EPS. The quarter’s net margin came in at 31.66%, while return on equity measured 102.94%.
Lilly increased its quarterly dividend distribution to $1.73, up from the prior $1.50. The annualized dividend now totals $6.92, translating to approximately 0.7% yield.
Shares opened Friday trading at $982.85. The 52-week trading range extends from $623.78 to $1,133.95. The stock’s 50-day moving average stands at $1,047.37, while the 200-day moving average registers $937.23.
Wall Street Coverage and Institutional Holdings
Institutional investors currently hold 82.53% of LLY shares. Several investment firms expanded their positions during Q3 2026, with KCM Investment Advisors increasing its holding by 14%, and M1 Capital Management boosting its stake by 10.8%.
Integrity Advisory Solutions initiated a new position valued at roughly $1.07 million in the quarter.
The overall analyst consensus registers as “Moderate Buy” with a mean price objective of $1,229.59. Wells Fargo elevated its target to $1,280 alongside an Overweight rating. Jefferies increased its target to $1,300, maintaining a Buy recommendation. Royal Bank of Canada initiated coverage with an Outperform rating and $1,250 price target.
Seven research analysts increased their earnings projections following the Q4 earnings release.
Lilly recently introduced its “Employer Connect” initiative, designed to facilitate employer-sponsored coverage for obesity medications, featuring Zepbound at a $449 single-patient KwikPen pricing structure.
Orforglipron, Lilly’s investigational oral GLP-1 compound, outperformed oral semaglutide in a Type 2 diabetes clinical trial across both primary and secondary efficacy measures.
